EXFORGE HCT

LOE Approaching

amlodipine valsartan and hydrochlorothiazide

NDAORALTABLET
Approved
Apr 2009
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
57

Mechanism of Action

Angiotensin 2 Receptor Antagonists

Pharmacologic Class:

Angiotensin 2 Receptor Blocker

Clinical Trials (5)

NCT06236061Phase 3Completed

Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

Started Apr 2024
718 enrolled
Hypertension
NCT01865188Phase 3Withdrawn

Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension

Started Apr 2014
0
Hypertension
NCT02062645Phase 4Completed

Study of Efficacy and Safety of CVAA489 in Hypertensive Patients

Started Feb 2014
115 enrolled
Essential Hypertension
NCT01692301Phase 2Completed

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

Started Dec 2012
454 enrolled
Hypertension
NCT01631864Phase 2Completed

Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects

Started Oct 2012
98 enrolled
HypertensionConcurrent Obesity